Children's Tumor Foundation

The Children's Tumor Foundation (CTF) is a United States-based 501(c)(3) nonprofit organization focused on neurofibromatosis and schwannomatosis, a group of genetic conditions that can cause tumors to develop on nerves throughout the body. Its work encompasses neurofibromatosis type 1 (NF1), NF2-related schwannomatosis and other forms of schwannomatosis. Because these disorders can affect many organ systems and vary substantially in severity, people living with NF may experience vision or hearing impairment, bone abnormalities, disfigurement, learning difficulties, chronic pain, neurological complications, and elevated risks of certain cancers. Established in 1978 as the National Neurofibromatosis Foundation, the organization initially concentrated on building a patient community, providing information, and supporting families. It progressively expanded into scientific research. During the 1980s and 1990s, CTF-backed work helped establish neurofibromatosis as a field of coordinated genetic and biomedical investigation, including research leading to identification of the NF1 and NF2 genes. The organization changed its name to Children's Tumor Foundation in 2005, reflecting a broader institutional identity and an increasingly active role in treatment development. CTF describes itself as a drug-discovery engine for NF. Rather than operating solely as a conventional grantmaker, it has developed a funder-partner model that connects patients, clinicians, academic scientists, biotechnology companies, pharmaceutical companies, and research institutions. Its programs have included early-career investigator awards, preclinical drug screening, collaborative therapeutic consortia, clinical-trial support, patient registries, biological specimen resources, and networks of specialist clinics. The stated objective is to shorten the path from scientific findings to therapies that can reach patients. The foundation's major research initiatives include the Drug Discovery Initiative, the NF Preclinical Drug Screening Consortium, the Neurofibromatosis Therapeutic Consortium, and the Synodos collaborations for NF1 and NF2. These programs are designed to coordinate laboratories, share data, test candidate treatments, and reduce duplication in a field where patient populations are relatively small and the biology is complex. CTF has also supported the development of clinical infrastructure, including an NF Clinic Network intended to promote care consistent with consensus guidelines. Beyond research, CTF provides educational material, patient and caregiver information, clinical-trial referrals, advocacy, and community events. Its patient registry is intended to help researchers identify potential trial participants while giving registrants information relevant to their manifestations of NF. The organization also convenes the annual NF Conference for scientists and clinicians and the NF Summit for patients, families, advocates, researchers, and care providers. Fundraising and awareness activities have included NF Walk, NF Endurance, Cupid's Undie Run, poker events, and a national gala. CTF advocates for public investment in NF research, including funding associated with the U.S. Department of Defense Congressionally Directed Medical Research Program Neurofibromatosis Research Program and the National Institutes of Health. Its overall positioning combines patient advocacy, research financing, translational science, clinical-network development, and community support. The available reference material does not identify a current headquarters address, current chief executive, or independently verified financial figures.

The Children's Tumor Foundation was established in 1978 as the National Neurofibromatosis Foundation by nurse Lynne Ann Courtemanche, neurologist Allen E. Rubenstein, and attorney Joel S. Hirschtritt. Its early mission was to help people affected by neurofibromatosis and their families obtain information, support, and a stronger community network. At that time, NF was poorly understood, and patients often faced fragmented diagnosis and care. The foundation broadened its role during the 1980s. In 1985 it convened the first major scientific meeting devoted to neurofibromatosis, creating a recurring forum for researchers and clinicians. That same year it began the Young Investigator's Award, a two-year program intended to help postdoctoral researchers and early-career scientists become independent investigators. CTF awarded its first research grants in 1988, helping establish what the organization describes as the first dedicated NF research program. Research supported through the foundation contributed to major genetic discoveries. Laboratories receiving CTF grants identified the NF1 gene in 1990 and the NF2 gene in 1993. These findings helped establish a molecular basis for the disorders and provided targets for subsequent biological and therapeutic research. In 1997, the organization added an international summer camp for young people affected by NF, extending its community mission beyond research funding. In the 2000s, CTF moved more deliberately toward translational science. It began a drug-discovery initiative in 2006 and developed a network of NF clinics beginning in 2007. The clinic initiative sought to connect specialist centers and encourage care based on shared clinical guidelines. In 2005, the organization changed its name to Children's Tumor Foundation. The new identity accompanied a shift from a primarily support-oriented foundation toward an organization seeking to accelerate treatments. The foundation's research model subsequently became more partnership-oriented. Its NF Preclinical Drug Screening Consortium was a multi-site effort designed to test candidate therapies in laboratory and animal models. In 2013, CTF worked with the NF Therapeutics Acceleration Program at Johns Hopkins School of Medicine on the Neurofibromatosis Therapeutic Consortium, continuing preclinical work and seeking to move promising approaches toward human studies. CTF also launched a patient registry in 2012 and a specimen biobank in 2013, providing resources for clinical-trial recruitment, research, and more tailored patient information. In 2014, CTF launched Synodos for NF2, a collaborative model bringing researchers from different institutions together with commitments to share data and coordinate work. A parallel Synodos for NF1 initiative was announced for the following year. Under the leadership described in the reference material for President and Chief Scientific Officer Annette Bakker, CTF increasingly presented itself as a catalyst and partner rather than only a grant distributor, drawing on a venture-style approach to selecting and advancing research opportunities. The organization continues to combine science and patient services. It supports the NF Conference for researchers and clinicians, the NF Summit for patients and families, educational publications, clinical-trial information, advocacy for public research funding, and fundraising activities such as NF Walk, NF Endurance, Cupid's Undie Run, poker tournaments, and a national gala. Its work links patients, medical professionals, researchers, and industry partners in pursuit of better care, new therapies, and ultimately cures for NF and schwannomatosis.

• 2014

  Synodos for NF2 established

  [1]Children's Tumor Foundationen.wikipedia.org

  The foundation launched a multi-institution collaboration focused on coordinated NF2 research and treatment discovery.

• 2013

  Specimen biobank and therapeutic consortium developed

  [1]Children's Tumor Foundationen.wikipedia.org

  CTF established a specimen resource and participated in the Neurofibromatosis Therapeutic Consortium with Johns Hopkins.

• 2012

  Patient registry launched

  [1]Children's Tumor Foundationen.wikipedia.org

  The foundation created a registry intended to support research, clinical-trial referrals, and personalized patient information.

• 2006

  Drug Discovery Initiative begins

  [1]Children's Tumor Foundationen.wikipedia.org

  CTF began an initiative supporting preclinical screening and therapeutic discovery for NF.

• 2005

  Name changed to Children's Tumor Foundation

  [1]Children's Tumor Foundationen.wikipedia.org

  The National Neurofibromatosis Foundation adopted its current name.

• 1993

  NF2 gene identified through supported research

  [1]Children's Tumor Foundationen.wikipedia.org

  A CTF-supported laboratory identified the gene associated with NF2.

• 1990

  NF1 gene identified through supported research

  [1]Children's Tumor Foundationen.wikipedia.org

  A laboratory supported by foundation grants identified the gene associated with NF1.

• 1988

  First research grants awarded

  [1]Children's Tumor Foundationen.wikipedia.org

  The foundation awarded its first grants, launching a dedicated neurofibromatosis research program.

• 1985

  First major NF scientific conference

  [1]Children's Tumor Foundationen.wikipedia.org

  CTF convened the first major scientific meeting focused on neurofibromatosis and began its Young Investigator's Award.

• 1978

  Organization established

  [1]Children's Tumor Foundationen.wikipedia.org

  The National Neurofibromatosis Foundation was established by Lynne Ann Courtemanche, Allen E. Rubenstein, and Joel S. Hirschtritt.

A patient-centered nonprofit research catalyst and drug-discovery partner for neurofibromatosis and schwannomatosis, combining scientific funding, clinical infrastructure, advocacy, and community services.

• Research funding and preclinical development · 2006

  Drug Discovery Initiative

  Introduced in 2006, the Drug Discovery Initiative supports laboratory screening and preclinical evaluation of potential NF therapies. It is intended to generate both in-vitro and in-vivo evidence that can help promising compounds move toward clinical development.

• Clinical-care network · 2007

  NF Clinic Network

  The NF Clinic Network connects specialist clinics and promotes care aligned with consensus guidelines. The reference material describes the network as serving patients through affiliated centers in the United States and linking clinical care with research and trial opportunities.

• Patient registry and research infrastructure · 2012

  NF Patient Registry

  Launched in 2012, the registry is designed to help accelerate treatment research by supporting clinical-trial referrals and providing participants with information relevant to their NF manifestations and available studies.

• Scientific conference · 1985

  NF Conference

  The annual NF Conference brings together researchers and clinicians working on neurofibromatosis and schwannomatosis. It began with CTF's 1985 scientific meeting and has developed into a major forum for presenting findings and encouraging collaboration.

• Patient and family conference

  NF Summit

  The NF Summit is a community-oriented gathering for patients, families, advocates, researchers, clinicians, volunteers, and event organizers. Educational sessions and networking are intended to improve understanding, support, and collaboration across the NF community.

• Early-career research award · 1985

  Young Investigator's Award

  Created in 1985, this two-year award supports postdoctoral and early-career investigators. Its purpose is to help researchers establish independent programs and build long-term scientific capacity in NF research.

• Collaborative research consortia · 2014

  Synodos for NF1 and Synodos for NF2

  These consortia bring investigators from multiple institutions into coordinated research programs. Their model emphasizes data sharing, collaboration across laboratories, and a collective effort to identify treatments for NF1 and NF2-related schwannomatosis.

• NF Walk

  United States

  A community fundraising and awareness program that brings together people affected by NF, families, supporters, and local organizers.

  Outcome. Supports fundraising, public awareness, and community participation.

  Source
• NF Endurance

  United States

  An endurance-oriented fundraising program associated with awareness and community support for neurofibromatosis.

  Outcome. Raises funds and visibility for the foundation's research and patient-support work.

  Source
• Cupid's Undie Run

  United States

  A fundraising event used to generate awareness and financial support for NF-related programs.

  Outcome. Contributes to fundraising and public engagement.

  Source
• National Gala

  United States

  A formal fundraising event supporting the foundation's research, advocacy, and community mission.

  Outcome. Provides philanthropic support and raises awareness of NF.

  Source

• 2014

  Created Synodos for NF2Strategy

  Background

  NF2 research involved multiple institutions and required more systematic sharing of data and experimental resources.

  Action taken

  CTF established a collaborative, multi-institution consortium focused on NF2 treatment discovery.

  Aftermath

  A comparable Synodos for NF1 initiative was announced for launch in the following year.

  Source

• 2008

  Began funding clinical trialsStrategy

  Background

  CTF sought to extend its impact beyond laboratory and preclinical research.

  Action taken

  The foundation added clinical-trial funding to its research portfolio.

  Aftermath

  Its activities covered a larger portion of the treatment-development pathway.

  Source

• 2006

  Shifted toward translational drug discoveryStrategy

  Background

  Basic genetic discoveries had created opportunities for developing treatments, but NF research required more coordinated preclinical work.

  Action taken

  CTF launched the Drug Discovery Initiative and began emphasizing a funder-partner model.

  Aftermath

  The foundation increasingly positioned itself as a catalyst connecting patients, scientists, institutions, and industry.

  Source

• 2005

  Adopted the Children's Tumor Foundation identityStrategy

  Background

  The former National Neurofibromatosis Foundation was expanding from patient support into translational research and treatment development.

  Action taken

  The organization changed its name to Children's Tumor Foundation.

  Aftermath

  The new identity accompanied a broader role spanning research, clinical care, advocacy, and patient services.

  Source

1. 1Children's Tumor Foundationen.wikipedia.org
2. 2Children's Tumor Foundation official websitectf.org